Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,229.51 -718.48 (-1.12%) CMC Crypto 200
1,304.48 -92.06 (-6.59%)
ABBV Jan 2025 200.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 03:13PM EDT
| Previous close | 2.8000 |
| Open | 2.5200 |
| Bid | 1.1900 |
| Ask | 1.6700 |
| Strike | 200.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.2400 - 2.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3.9k |
- Yahoo Finance Video
Abbvie stock falls amid growing biosimilar competition
Pharmaceutical giant AbbVie Inc. (ABBV) shares came under pressure as the market closed on Friday, following the disappointing first quarter sales performance of the company's arthritis drug, Humira. The company forecast that Humira's sales could slow further in the face of heightened competition. Yahoo Finance's health reporter Anjalee Khemlani breaks down the details, providing insight into the rise of biosimilars in the market. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance. This post was written by Angel Smith
- GuruFocus.com
AbbVie Inc (ABBV) Q1 2024 Earnings Call Transcript Highlights: Surpassing Expectations with ...
Discover how AbbVie Inc (ABBV) exceeded forecasts with robust revenue growth and strategic expansions in its latest quarterly earnings.
© 2024 Yahoo. All rights reserved.